Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
https://www.thelancet.com/journals/lancet/article/...
Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to
remdesivir and 79 to placebo)
https://www.thelancet.com/journals/lancet/article/...
In its clinical trial, whose full results are yet to be released, the US National Institute of Allergy and Infectious Diseases (NIAID) found that
remdesivir cut the duration of symptoms from 15 days down to 11.
https://www.bbc.com/news/world-us-canada-52511270